Cardax Inc
OTC:CDXI

Watchlist Manager
Cardax Inc Logo
Cardax Inc
OTC:CDXI
Watchlist
Price: 0.0001 USD Market Closed
Market Cap: 80.3 USD

Operating Margin
Cardax Inc

-584.8%
Current
-543%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-584.8%
=
Operating Profit
-2.9m
/
Revenue
500.7k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Cardax Inc
OTC:CDXI
80.3 USD
-585%
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
498.9B USD
27%
CH
Roche Holding AG
SIX:ROG
261.4B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP
24%
CH
Novartis AG
SIX:NOVN
210.3B CHF
33%
US
Merck & Co Inc
NYSE:MRK
264.8B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK
42%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
11%
US
Pfizer Inc
NYSE:PFE
143.2B USD
29%
No Stocks Found

Cardax Inc
Glance View

Market Cap
80.3 USD
Industry
Pharmaceuticals

Cardax, Inc. is a development stage biopharmaceutical company, which engages in development of pharmaceuticals for chronic diseases driven by inflammation. The company is headquartered in Honolulu, Hawaii and currently employs 10 full-time employees. The company went IPO on 2012-01-30. The firm has a commercial business unit that markets dietary supplements for inflammatory health. The firm's product platform consists of CDX-101, astaxanthin pharmaceutical candidate, that is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. CDX-301, the Company’s zeaxanthin pharmaceutical candidate, is being developed for macular degeneration. Its pharmaceutical candidates are in pre-clinical development, including the planning of investigational new drug (IND) enabling studies. ZanthoSyn is a physician recommended astaxanthin dietary supplement for inflammatory health. The firm sells ZanthoSyn primarily through wholesale and e-commerce channels.

CDXI Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-584.8%
=
Operating Profit
-2.9m
/
Revenue
500.7k
What is the Operating Margin of Cardax Inc?

Based on Cardax Inc's most recent financial statements, the company has Operating Margin of -584.8%.

Back to Top